Cancer requires treatment, but what if low-risk lesions are no longer called cancer? Drs. Kathy Miller and Maurie Markman look at possible effects on screening, treatment, and public perception.

Long-term results from the Prostate Cancer Prevention Trial raise new questions for clinicians to discuss with their patients, reports Dr. Gerald Chodak.

Dr. John Marshall takes to his electronic chalkboard to tackle the problem of coordinating the separate agendas of cancer stakeholders, and finds a simple yet elegant solution.

A public campaign in Sweden to curb unnecessary imaging in low-risk prostate cancer should set an example for the United States, says Dr. Gerald Chodak.

Experts at the recent Prostate Cancer World Congress tried to simplify conflicting guidelines about prostate cancer screening, but did they just add to the confusion? Dr. Gerald Chodak comments.

George Lundberg talks about the RUC -- how its structure and evolution have harmed healthcare, and the necessity of changing it.

A new study suggests that following certain lifestyle guidelines may lower a man's risk for aggressive prostate cancer, but how great an impact could it have? Dr. Gerald Chodak examines the evidence.

Dr. Gerald Chodak discusses a highly publicized study linking omega-3 fatty acids to prostate cancer and explains why the conclusions should not be taken to heart.

This F1000 commentary reports on a study whose findings conclude that key and critical phases of care can significantly benefit from simple checklists.

Is the nation on the verge of a healthcare provider shortage, or are clinicians being phased out by algorithms?